46 results about "Hypermetropia" patented technology

A method and apparatus are disclosed for controlling optical aberrations to alter relative curvature of field by providing ocular apparatuses, systems and methods comprising a predetermined corrective factor to produce at least one substantially corrective stimulus for repositioning peripheral, off-axis, focal points relative to the central, on-axis or axial focal point while maintaining the positioning of the central, on-axis or axial focal point on the retina. The invention will be used to provide continuous, useful clear visual images while simultaneously retarding or abating the progression of myopia or hypermetropia.

A method and apparatus are disclosed for controlling optical aberrations to alter relative curvature of field by providing ocular apparatuses, systems and methods comprising a predetermined corrective factor to produce at least one substantially corrective stimulus for repositioning peripheral, off-axis, focal points relative to the central, on-axis or axial focal point while maintaining the positioning of the central, on-axis or axial focal point on the retina. The invention will be used to provide continuous, useful clear visual images while simultaneously retarding or abating the progression of myopia or hypermetropia.

The invention relates to a method for identification of substances which are applicable for treatment or prevention of an insufficient longitudinal growth of the eye (hypermetropia) or for treatment or prevention of an excessive longitudinal growth of the eye (myopia); substances identified by the method for treating or preventing conditions related to the longitudinal growth of the eye; substances and mixtures of substances for the preparation of a pharmaceutical composition for the treatment or prevention of abnormal growth of the axial length of the eye. The identification involves measuring the effect of the substances on the retinal pigment epithelium of the eye, e.g. by detecting the metabolic effect of the substance on the retinal epithelium, the effect on the standing potential or the effect on the proteoglycanes of the scleral tissue of the eye, by way of EOG examination, by way on the size of the so-called c-wave in ERG-recordings, or by the state of the Ca<2+>-channels or on the [<3>H]-ryanodine receptors of the retinal pigment epithelium.

There are described an excimer laser unit and a method of controlling the unit to perform cornea ablation to reduce presbyopia, wherein the excimer laser unit is controlled to form on the cornea a photoablative pattern inducing a fourth-order ocular aberration, in particular a positive spherical aberration. More specifically, an aberrometric map of the eye is first acquired indicating the visual defects of the eye, which include second-order visual defects such as hypermetropia, astigmatism, and myopia, and higher-order visual defects such as spherical aberration; if the detected spherical aberration is negative, it is reduced by numerically increasing its absolute value to obtain an overcorrect photoablative inducing positive spherical aberration; conversely, if the detected spherical aberration is positive, its sign is changed and its absolute value increased numerically to obtain an overcorrect photoablative pattern inducing positive spherical aberration; and the photoablative pattern so generated is supplied to the excimer laser unit for implementation on the cornea.

A binocular vision apparatus allows a patient to view objects through the apparatus with polychromatic light and monochromatic aberration correction, such that the chromatic aberration of the eye can be combined with the monochromatic aberration correction, so as to provide a more accurate determination of vision quality. The binocular vision apparatus provides left and right viewing optics that can substantially maintain the line of sight of each eye, such that objects can be viewed in a room with 3D depth perception corresponding to the distance of the object from the patient. As both near and far objects can be viewed with binocular aberration correction, the patient can alternate binocular viewing between near and far vision with chromatic aberration so as to evaluate a proposed treatment such as a presbyopia correction.

An optometric apparatus and an optometric method which perform an accurate eye examination on people who have a wide range of refractive powers with astigmatism, myopia or hyperopia, and which are also applicable especially to those with mixed astigmatism are provided. The apparatus performs a subjective eye examination by prompting a subject to view test symbols displayed on a computer screen by one of the right and left eyes at a time. The system includes astigmatic axis angle determination means which displays test symbols for determining an astigmatic axis angle and then determines the astigmatic axis angle, hyperopia and myopia determination means which displays test symbols for determining hyperopia or myopia in two orthogonal orientations selected based on the determined astigmatic axis angle, and determines hyperopia or myopia at the astigmatic axis angle and at an angle orthogonal thereto, and refractive power determination means which displays test symbols for determining a refractive power in two orthogonal orientations selected based on the determined astigmatic axis angle and determines a refractive power at the astigmatic axis angle and at an angle orthogonal thereto.

This invention relates to a novel, non-progressive trifocal ophthalmic lens comprising distance-vision, near-vision and intermediate-vision optic fields. The non-progressive element of the trifocal lens is achieved by blending the transition zones between the different fields of vision. Further, unlike traditional trifocal lenses, the transition zones of the present invention are of uniform width, providing a smooth transition between the different optic fields that can not be easily discerned by a person observing a wearer of said ophthalmic lens.

The invention relates to a medicament, the active principle of which is a leucine and, for example, a N-ACETYL-DL-LEUCINE. It can be applied to the prevention and / or treatment of eye diseases or disorders and especially of hereditary dystrophies of the retina, glaucomatous neuropathy, glaucoma, macular degeneration, myopia, presbyopia, hypermetropia, astigmatism, all the ophtalmologic diseases or disorders inducing a decrease of visual function and / or age-related physiological vision decline.

The invention relates to an ophthalmic lens for long-sighted and intermediate vision comprising a complex surface provided with an optical centre, a substantially umbilicated meridian line and an average size sphere progression on the top surface equal to or greater than 0.50 diopters. The complex surface is provided in the top part thereof with a long-sighted vision area which is formed by cylinder points equal to or less than 0.25 diopters and covers an angular sector focused on the optical centre and whose angle is equal to 160°. Said complex surface also comprises an average size substantially constant sphere on the meridian line in the long-sighted vision area and a progression length equal to or less than 12 mm. Said progression length is defined as a vertical distance between the optical centre and a median point for which the average sphere if greater than 85% of progression on the average sphere in the optical centre. The inventive lens is suitable for driving and prescribed to persons having additional prescription greater than a power progression, whereby a correction adaptable to the power prescription of a longsighted vision person is provided in the top part of the lens. The lower part of the lens ensures the correction needed for an intermediate vision person.

Lenses are designed using wavefront measurements amenable to correction factors for near and far vision as well as pupil size to slow or stop myopia progression.